Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma

Journal of Cancer Research and Clinical Oncology

Volumn 133, Issue 11, 2007, Pages 897-901

  Terheyden, Patrick ^a   Hofmann, Maja Ann ^b   Weininger, M ^a   Bröcker, Eva B ^a   Becker, Jürgen C ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiogenesis; Chemotherapy; Melanoma; Metastases; Therapy

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; DEXAMETHASONE; FOTEMUSTINE; PACLITAXEL; TEMOZOLOMIDE; TROPISETRON; VASCULOTROPIN ANTIBODY; VINDESINE;

ABSENCE OF SIDE EFFECTS; ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW DEPRESSION; CANCER CHEMOTHERAPY; CASE REPORT; COMBINATION CHEMOTHERAPY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; LEUKOPENIA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MELANOMA; MONOTHERAPY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; SKIN METASTASIS; THROMBOCYTOPENIA; TUMOR VOLUME;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 36849048282     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0251-8     Document Type: Article

References (22)

1. Beierle EA, Nagaram A, Dai W, Iyenger M, Chen MK (2005) VEGF-mediated survivin expression in neuroblastoma cells. J Surg Res 127:21-28
2. Brennecke S, Deichmann M, Naeher H, Kurzen H (2005) Decline of angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastastic melanoma. Melanoma Res 15:515-522
3. Demirkesen C, Buyukpinarbasili H, Ramazanoglu R, Oguz O, Mandel NM, Kaner G (2006) The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblast growth factor. Pathology 38:132-137
4. Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748-759
5. Ferrara N, Hillan KJ, Gerber HP, Novotny W (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 3:391-400
6. Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65:671-680
7. Giatromanolaki A, Sivridis E, Koukourakis MI (2006) Angiogenesis in colorectal cancer: prognostic and therapeutic implications. Am J Clin Oncol 29:408-417
8. Gille J (2006) Antiangionenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. Exp Dermatol 15:175-186
9. Güven K, Kittler H, Wolff K, Pehamberger H (2001) Cisplatin and carboplatin combination as second-line chemotherapy in dacarbazine resistant melanoma patients. Melanoma Res 11:411-415
10. Hicklin DJ, Ellis LM (2005) Role of vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011-1027
11. Houben R, Becker JC, Kappel A, Terheyden P, Bröcker EB, Götz R, Rapp UR (2004) Constitutive activation of the Ras-Raf signaling pathway in metastastic melanoma is associated with poor prognosis. J Carcinog 3:6
12. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluororuracil, and leucovorin for metastastic colorectal cancer. N Engl J Med 350:2335-2342
13. Lev DC, Ruiz M, Mills L, McGary EC, Price JC, Bar-Eli M (2003) Dacarbazine causes transcriptional up-regulation of interleukin-8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2:753-763
14. 6-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol 211:97-105
15. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550
16. Shih T, Lindley C (2006) Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28:1779-1802
17. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651-1656
18. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736
19. Tran J, Rak J, Sheehan C, Saibil SD, LaCasse E, Korneluk RE, Kerbel RS (1999) Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 264:781-788
20. Ugurel S, Rappl G, Tilgen W, Reinhold U (2001) Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 19:577-583
21. Weis SM, Cheresh DA (2005) Pathophysiological consequences of VEGF-induced vascular permeability. Nature 437:497-504
22. Zhang L, Hannay JAF, Liu J, Das P, Zhan M, Nguyen T, Hicklin DJ, Yu D, Pollock RE, Lev D (2006) Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumour growth, metastasis, and chemoresistance. Cancer Res 66:8770-8778